Fused imide derivatives
By developing fused imide compounds as Protac molecules, which are combined with target proteins and E3 ubiquitin ligases, specific degradation of BTK protein was achieved, solving the problem of poor BTK targeted degradation in existing technologies and improving the therapeutic effect on B-cell related diseases.
CN119823111BActive Publication Date: 2026-05-05CHIA TAI TIANQING PHARMA GRP CO LTD
2 Cites 0 Cited by
Patent Information
- Application Number
- CN202411790610.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2022-11-11
- Filing Date
- 2022-11-18
- Publication Date
- 2026-05-05
- Estimated Expiration
- 2042-11-18
AI Technical Summary
Technical Problem
Existing technologies have difficulty effectively targeting and degrading Bruton's tyrosine kinase (BTK) protein, resulting in poor treatment outcomes for B-cell-related diseases such as B-cell non-Hodgkin's lymphoma and rheumatoid arthritis.
Method used
We developed fused imide compounds as Protac molecules, which induce the degradation of target proteins by binding to target proteins and E3 ubiquitin ligases, thereby achieving specific degradation of BTK.
Benefits of technology
It achieves efficient degradation of BTK protein, improves the therapeutic effect on B-cell related diseases, and provides a safer therapeutic target.
✦ Generated by Eureka AI based on patent content.
Abstract
This application belongs to the field of medicinal chemistry and relates to fused imide derivatives of Formula I, their preparation methods, pharmaceutical compositions containing the compound, and their use in treating related diseases (e.g., cancer).
Need to check novelty before this filing date? Find Prior Art